Insider Selling: SiBone (NASDAQ:SIBN) CEO Sells 38,006 Shares of Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 38,006 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $20.05, for a total value of $762,020.30. Following the completion of the transaction, the chief executive officer directly owned 379,256 shares in the company, valued at approximately $7,604,082.80. This represents a 9.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Laura Francis also recently made the following trade(s):

• On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The shares were sold at an average price of $20.12, for a total value of $522,556.64.
• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $78,538.46.
• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The shares were sold at an average price of $19.46, for a total value of $1,009,662.64.

SiBone Stock Performance

SIBN traded down $0.21 during midday trading on Wednesday, reaching $19.47. The company had a trading volume of 407,809 shares, compared to its average volume of 610,528. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. The business has a 50-day moving average of $18.89 and a two-hundred day moving average of $16.43. The company has a market cap of $863.49 million, a P/E ratio of -57.26 and a beta of 0.66. SiBone has a 1 year low of $11.48 and a 1 year high of $21.89.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. The firm had revenue of $56.01 million for the quarter, compared to analysts’ expectations of $55.34 million. As a group, equities research analysts predict that SiBone will post -0.40 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SIBN has been the topic of a number of recent analyst reports. Truist Financial raised their target price on shares of SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. UBS Group upped their price target on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, TD Cowen increased their price objective on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $24.50.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Versant Capital Management Inc grew its holdings in shares of SiBone by 102.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after purchasing an additional 887 shares during the period. D.A. Davidson & CO. increased its position in shares of SiBone by 5.7% during the 1st quarter. D.A. Davidson & CO. now owns 36,882 shares of the company’s stock worth $466,000 after purchasing an additional 1,991 shares during the last quarter. Diversified Trust Co raised its holdings in SiBone by 10.8% in the 1st quarter. Diversified Trust Co now owns 24,335 shares of the company’s stock valued at $307,000 after buying an additional 2,375 shares during the period. State of Wyoming lifted its position in SiBone by 70.8% in the first quarter. State of Wyoming now owns 10,832 shares of the company’s stock valued at $137,000 after buying an additional 4,490 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its position in SiBone by 58.2% in the first quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock valued at $372,000 after buying an additional 10,848 shares during the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SiBone Company Profile

SI-BONE, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of disorders affecting the sacroiliac joint, which connects the spine to the pelvis. The company’s technology is intended to support minimally invasive procedures for patients with sacroiliac joint dysfunction and related conditions.

Its product portfolio includes the iFuse Implant System, a family of triangular titanium implants designed to stabilize and fuse the sacroiliac joint.